Mark Wildgust News Today

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

The FDA has approved a label expansion for ibrutinib with an oral suspension formulation in all current indications.

Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.

BioPharma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

What will it take to improve cancer diagnosis such that oncologists have the best chance of curing the disease?